Selvita And Orion Pharma Will Collaborate on SEL103 - Alzheimer’s Disease Program
Selvita sp. z o.o. and Orion Corporation from Espoo, Finland announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita’s proprietary program for the treatment of Alzheimer’s disease and other cognitive disorders. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.
Under the terms of the agreement, Selvita will be responsible for the discovery and early preclinical development of small molecules and will receive upfront and research funding as well as milestone payments from Orion subject to the progress of the development program. After the selection of a lead compound, Orion will be responsible for the further steps of the program with global commercialization rights. The financial and other details of the collaboration agreement remain between the parties.
The companies are planning to conduct a broad-based global research and development program which will combine the resources of Orion’s experienced CNS research and development team with Selvita’s competencies in discovery chemistry and biology assays. In collaboration, both parties can achieve joint goals faster and with better success than by doing the work alone.
Other news from the department business & finance
